When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Retinitis pigmentosa

Evidence last reviewed: 14 Feb 2026
Topic last updated: 09 Oct 2025

Summary

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • positive family history
  • presence of an associated syndrome
  • decreased peripheral vision
  • night blindness
  • impaired dark adaptation
  • decreased central acuity
  • atrophy of retinal pigment epithelium
  • bone spicule pigmentation
Todos los datos

Otros factores de diagnóstico

  • waxy pale optic nerve
  • photopsias
  • refractive error
  • cataracts
  • retinal vascular attenuation
  • cystoid macular edema
  • vitreous cells
  • glare from bright lights
  • abnormal color vision
  • keratoconus
  • glaucoma
  • optic nerve head drusen
  • Coats-like retinopathy
  • Leber congenital amaurosis
Todos los datos

Factores de riesgo

  • family history
  • presence of an associated syndrome
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • assessment of visual acuity
  • anterior segment exam and intraocular pressure measurement
  • full field perimetry
  • full field electroretinogram (ERG)
Todos los datos

Pruebas diagnósticas que deben considerarse

  • elevated final dark-adapted threshold
  • optical coherence tomography (OCT)
  • genetic testing
  • adaptive optics imaging
  • wide-field fundus autofluorescence (FAF)
Todos los datos

Pruebas emergentes

  • whole exome sequencing

Algoritmo de tratamiento

Agudo

all patients

Colaboradores

Autores

Lesley Everett , MD, PhD, MPhil

Assistant Professor of Ophthalmology

Casey Eye Institute

Oregon Health and Sciences University

Divisions of Ophthalmic Genetics and Retina

Portland

OR

Divulgaciones

LAE is supported by a Foundation Fighting Blindness Career Development Grant.

Mark E. Pennesi, MD, PhD
Mark E. Pennesi

Professor

Casey Eye Institute

Oregon Health and Sciences University

Portland

OR

Divulgaciones

MEP serves on the scientific advisory board and executive committee for the Foundation Fighting Blindness.

Paul Yang, MD, PhD
Paul Yang

Associate Professor

Casey Eye Institute

Oregon Health and Sciences University

Portland

OR

Divulgaciones

PY acted as a consultant for 4D Molecular Therapeutics, AAVantgarde Bio (IDMC), Adverum, Astellas, Beacon Therapeutics, BlueRock Therapeutics, Eluminex Biosciences, Foundation Fighting Blindness (SAB), Janssen (DSMB), MieraGTx (DSMB), Nanoscope Therapeutics (SAB), and TeamedOn.

Agradecimientos

Dr Lesley Everett, Dr Mark E. Pennesi, and Dr Paul Yang would like to gratefully acknowledge Dr Richard G. Weleber and Dr Peter J. Francis, previous contributors to this topic.

Divulgaciones

RGW has served as a consultant to Novartis, Pfizer, and Wellstat, is a member of the scientific advisory board for Applied Genetic Technologies Corp, and serves on the scientific advisory board for the Foundation Fighting Blindness (the relationship has been reviewed and managed by Oregon Health & Science University). RGW also reports having received grants and personal fees from the Foundation Fighting Blindness and Applied Genetic Technologies Corp, and other support from Sanofi-Fovea, all outside the submitted work. In addition, RGW has a patent (US patent 8,657,446, Method and apparatus for visual field monitoring, also known as Visual Field Monitoring and Analysis, or VFMA, which has not been issued). PJF declares that he has no competing interests.

Revisores por pares

Scott Fraser, MD, FRCS (Ed), FRCOphth

Consultant Ophthalmologist

Sunderland Eye Infirmary

Sunderland

UK

Divulgaciones

SF declares that he has no competing interests.

Elias Traboulsi, MD

Professor of Ophthalmology

Director

Center for Genetic Eye Diseases

Cole Eye Institute

Cleveland Clinic

Cleveland

OH

Divulgaciones

ET declares that he has no competing interests.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

American Academy of Ophthalmology. Comprehensive adult medical eye evaluation PPP. Nov 2020 [internet publication].Texto completo

American Academy of Ophthalmology. Guidelines on clinical assessment of patients with inherited retinal degenerations - 2022. Oct 2022 [internet publication].Texto completo

Robson AG, Frishman LJ, Grigg J, et al. ISCEV Standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol. 2022 Jun;144(3):165-77.Texto completo  Resumen

American Academy of Ophthalmology. Recommendations for genetic testing of inherited eye diseases. February 2014 [internet publication].Texto completo

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad